<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03984188</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00209008</org_study_id>
    <nct_id>NCT03984188</nct_id>
  </id_info>
  <brief_title>Effectiveness of Low-dose Theophylline for the Management of Biomass-associated COPD in Uganda</brief_title>
  <official_title>Effectiveness of Low-dose Theophylline for the Management of Biomass-associated COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide,
      and over 90% of COPD-related deaths occurring in low- and middle-income countries (LMICs).
      Household air pollution (HAP) - from burning solid fuels such as wood, dung, agricultural
      crop waste, and coal for energy - is the primary risk factor for COPD in these settings.
      Biomass-related COPD has a distinct histopathology, phenotype and inflammatory profile when
      compared to tobacco mediated COPD. Despite the high global burden of biomass-related disease,
      little is known about the effectiveness of pharmacotherapies for biomass-related COPD; to
      date, no clinical trials have focused specifically on treatment of biomass-related COPD. This
      study proposes to assess the health impact of biomass-related COPD and test the effectiveness
      of low dose theophylline compared to standard therapy among adults with biomass-related COPD
      in Uganda with the aim to assess whether low-dose theophylline improves respiratory symptoms,
      decreases the inflammatory profile of serum biomarkers and whether administration attenuates
      the effect of HAP on lung function. The study additionally aims to assess whether low-dose
      theophylline is a cost-effective intervention based on the incremental cost-effectiveness
      ratio and a range of willingness to pay thresholds.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in St. George Respiratory Questionnaire score (SGRQ)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>The St. George Respiratory Questionnaire score comprises of 50 items and consists of two parts. The first part pertains to symptoms and the second pertains to functional status as well as social and psychological impact of disease. Overall scores ranges between 0 and 100 with higher scores indicating more limitations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cost-Effectiveness as assessed by the Short Form 36 (SF-36)</measure>
    <time_frame>1 year</time_frame>
    <description>Incremental cost-effectiveness using the Short From 36 score comprising 36 items. The SF-36 consists of eight scaled domains (vitality, physical functioning, body pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) each transformed into a 0-100 scale. Lower scores signify higher levels of disability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in forced expiratory volume in one second (FEV1)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>FEV1 (L) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in forced vital capacity (FVC)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>FVC (L) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peak expiratory flow (PEF)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>PEF (L/min) as measured through spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood levels of high sensitivity C reactive protein (hs-CRP)</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>Blood levels of hs-CRP (mg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood levels of fibrinogen</measure>
    <time_frame>Baseline, 6 months, 1 year</time_frame>
    <description>Blood levels of fibrinogen (mg/dL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>COPD</condition>
  <condition>COPD Exacerbation</condition>
  <condition>COPD Exacerbation Acute</condition>
  <condition>Pollution Related Respiratory Disorder</condition>
  <condition>Pollution; Exposure</condition>
  <arm_group>
    <arm_group_label>Low-dose Theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant in this group will receive low-dose theophylline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant in this group will receive a placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline ER</intervention_name>
    <description>200mg ER low-dose theophylline taken orally daily</description>
    <arm_group_label>Low-dose Theophylline</arm_group_label>
    <other_name>Low-dose Theophylline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Manufactured methylcellulose placebo tablet taken orally daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 40 years;

          -  Full-time resident of Nakaseke, Uganda

          -  post-bronchodilator FEV1/FVC &lt; the lower limit of normal of the Global Lung Initiative
             Mixed Ethnic reference population

          -  Grade B-D COPD; 5) Daily biomass exposure

        Exclusion Criteria:

          -  Plans to move out of the study area within one year

          -  Uncontrolled hypertension

          -  Pregnancy

          -  Current use of chronic respiratory medications [Long-acting beta-adrenoceptor agonist
             (LABA), Long-acting muscarinic antagonists (LAMA), inhaled corticosteroids (ICS)]

          -  History of post-treatment pulmonary tuberculosis

          -  ≥10 pack year tobacco smoking history

          -  Known intolerance or contraindication to theophylline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trishul Siddharthan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trishul Siddharthan, MD</last_name>
    <phone>(410) 955-3467</phone>
    <email>tsiddhar@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phabiola Herrera, MD</last_name>
    <phone>443.287.1971</phone>
    <email>pherrer2@jhmi.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Bonjour S, Adair-Rohani H, Wolf J, Bruce NG, Mehta S, Prüss-Ustün A, Lahiff M, Rehfuess EA, Mishra V, Smith KR. Solid fuel use for household cooking: country and regional estimates for 1980-2010. Environ Health Perspect. 2013 Jul;121(7):784-90. doi: 10.1289/ehp.1205987. Epub 2013 May 3.</citation>
    <PMID>23674502</PMID>
  </reference>
  <reference>
    <citation>Siddharthan T, Grigsby MR, Goodman D, Chowdhury M, Rubinstein A, Irazola V, Gutierrez L, Miranda JJ, Bernabe-Ortiz A, Alam D, Kirenga B, Jones R, van Gemert F, Wise RA, Checkley W. Association between Household Air Pollution Exposure and Chronic Obstructive Pulmonary Disease Outcomes in 13 Low- and Middle-Income Country Settings. Am J Respir Crit Care Med. 2018 Mar 1;197(5):611-620. doi: 10.1164/rccm.201709-1861OC.</citation>
    <PMID>29323928</PMID>
  </reference>
  <reference>
    <citation>Moran-Mendoza O, Pérez-Padilla JR, Salazar-Flores M, Vazquez-Alfaro F. Wood smoke-associated lung disease: a clinical, functional, radiological and pathological description. Int J Tuberc Lung Dis. 2008 Sep;12(9):1092-8.</citation>
    <PMID>18713510</PMID>
  </reference>
  <reference>
    <citation>Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. Chronic Obstr Pulm Dis. 2014 May 6;1(1):23-32. doi: 10.15326/jcopdf.1.1.2013.0004. Review.</citation>
    <PMID>28848808</PMID>
  </reference>
  <reference>
    <citation>Aït-Khaled N, Enarson D, Bousquet J. Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management. Bull World Health Organ. 2001;79(10):971-9. Epub 2001 Nov 1.</citation>
    <PMID>11693980</PMID>
  </reference>
  <reference>
    <citation>Beran D, Zar HJ, Perrin C, Menezes AM, Burney P; Forum of International Respiratory Societies working group collaboration. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med. 2015 Feb;3(2):159-170. doi: 10.1016/S2213-2600(15)00004-1. Review.</citation>
    <PMID>25680912</PMID>
  </reference>
  <reference>
    <citation>Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc. 2005;2(4):334-9; discussion 340-1. Review.</citation>
    <PMID>16267358</PMID>
  </reference>
  <reference>
    <citation>Ford PA, Durham AL, Russell RE, Gordon F, Adcock IM, Barnes PJ. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest. 2010 Jun;137(6):1338-44. doi: 10.1378/chest.09-2363. Epub 2010 Mar 18.</citation>
    <PMID>20299628</PMID>
  </reference>
  <reference>
    <citation>Rivera RM, Cosio MG, Ghezzo H, Salazar M, Pérez-Padilla R. Comparison of lung morphology in COPD secondary to cigarette and biomass smoke. Int J Tuberc Lung Dis. 2008 Aug;12(8):972-7.</citation>
    <PMID>18647460</PMID>
  </reference>
  <reference>
    <citation>Mendis S, Fukino K, Cameron A, Laing R, Filipe A Jr, Khatib O, Leowski J, Ewen M. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007 Apr;85(4):279-88.</citation>
    <PMID>17546309</PMID>
  </reference>
  <reference>
    <citation>Zhou Y, Wang X, Zeng X, Qiu R, Xie J, Liu S, Zheng J, Zhong N, Ran P. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006 Sep;11(5):603-10.</citation>
    <PMID>16916334</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomass Associated COPD</keyword>
  <keyword>Low-dose Theophylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

